Please login to the form below

Not currently logged in
Email:
Password:

tumours

This page shows the latest tumours news and features for those working in and with pharma, biotech and healthcare.

Merck’s Keytruda meets survival challenge in NSCLC

Merck’s Keytruda meets survival challenge in NSCLC

The new data “has the potential to change the treatment paradigm”for NSCLC patients whose tumours are either PD-L1-negative or untested, said Roger Perlmutter, head of Merck Research Laboratories. ... the response rate compared to chemotherapy in

Latest news

More from news
Approximately 7 fully matching, plus 926 partially matching documents found.

Latest Intelligence

  • Accelerating innovation Accelerating innovation

    leadership in neuroendocrine tumours - any therapeutic solutions [there] would be very interesting to us.”. ... sales muscle to go head-to-head with the very biggest players in tumour types like breast or lung.

  • Gene therapy Gene therapy

    Would there be off-target effects? Or challenges of tumour heterogeneity? And how easily would resistance to such an overtly targeted therapy arise?

  • Deal Watch March 2017 Deal Watch March 2017

    650. CytomX Therapeutics. BMS. Strategic collaboration. Probody platform to enhance tumour-targeting of antibodies. ... BioLineRx. Acquisition. Portfolio, including AGI-134, synthetic alpha-GaI immunotherapy for solid tumours.

  • Deal Watch February 2017 Deal Watch February 2017

    With a potential headline value of just over $2bn and $250m upfront, this deal brings Seattle Genetics, an ADC specialist itself, a product candidate that covers multiple solid tumour indications, including ... Acquisition - company. 2, 475. Immunomedics/

  • Deal Watch January 2017 Deal Watch January 2017

    IBM Watson Health/ Illumina. Partnership to integrate Watson for Genomics into Illumina's BaseSpace Sequence Hub and tumour sequencing process to expand access to genomic data.

More from intelligence
Approximately 0 fully matching, plus 58 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest from PMHub

  • emotive choose a charity to support in 2016

    year. The winner, The Brain Tumour Charity, is the UK’ s largest charitable foundation dedicated to fighting brain tumours. ... Its vision is a world where brain tumours are defeated and the diagnosis of a brain tumour is no longer a death sentence.

  • Eat, Sleep, Run, Repeat…

    ongoing annual fundraising activities for emotive’ s 2016 nominated charity, The Brain Tumour Charity. ... As well as providing incredible support to those living with brain tumours and their family, The Brain Tumour Charity also fund pioneering

  • Immunotherapy in oncology

    This can include anti-tumour immunity and tumour-promoting inflammation; the process is known as immunoediting. ... One of the phenomenon we have seen with products we have worked with is tumour flare, where tumours or lesions increase before they can

  • Our client services director walks the talk

    As part of our ongoing annual fundraising activities for emotive’ s 2016 nominated charity, we will be making a donation to  The Brain Tumour Charity, which provides incredible support to those ... The Brain Tumour Charity also fund pioneering

  • emotive does The Vitality British 10k London Run

    As well as another medal for the cabinet, we managed to raise over £650 for emotive’ s nominated 2016 charity, The Brain Tumour Charity. ... The charity helps improve the lives of those affected by brain tumours.

More from PMHub
Approximately 0 fully matching, plus 26 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SpotMe

SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics